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Summary Cytogenetic investigation was performed on direct preparations of 15 endometrial cancers showing different histotypes. Clonal
abnormalities were found in 11 out of 13 analysable cases. The modal chromosome number was near diploid in all cases. The abnormal
karyotypes contained relatively simple numerical or structural aberrations in the majority of tumours. In contrast, two neoplasms with serous
papillary and mixed mullerian morphological features shared multiple complex changes as well as cytogenetic evidence of intratumoral
heterogeneity. The most frequent chromosome abnormality in our series of endometrial neoplasms was 6q deletion, which was detected in
serous papillary, endometrioid and mixed mullerian tumours. The loss of the 6q region, which is also frequently involved in ovarian carcinoma,
suggests a relationship between endometrial and ovarian cancers based on a common histogenesis.
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Endometrial cancer is the most common gynaecological malig-
nancy in Italy, accounting for 42% of female genital tract cancers
diagnosed from 1983 to 1987 as reported in the Varese Cancer
Register (Zanetti and Crosignani, 1992).
The pathogenesis of endometrial carcinoma is heterogeneous,
and two different clinical entities referred to as type I and type II
can be distinguished (Kurman et al, 1994). Type I is more frequent
in younger women and often associated with unopposed oestrogen
exposure. It is histologically endometrioid and usually well differ-
entiated, of moderate aggressiveness and frequently preceded by
well-defined precancerous lesions (Bokhman, 1983; Smith and
McCartney, 1985). Type II cancer includes serous papillary, clear
cell and undifferentiated carcinomas that are not associated with
well-identified precursor lesions. It is rarer and clinically more
aggressive than type I cancer and is usually diagnosed in older
women without a history ofoestrogen exposure.
In addition to these two types ofendometrial cancer, the malig-
nant mixed mullerian tumour can be considered as a rare, but very
aggressive, neoplasm.
Until now, little has been known about the process oftumorige-
nesis ofthe two main types ofendometrial carcinoma. Cytogenetic
and molecular genetic studies can provide information that may be
relevant for the pathogenesis and may contribute to the identifica-
tion ofspecific types oftumourwith different biological behaviour.
To date, there have been relatively few studies on clonal cyto-
genetic abnormalities in endometrial cancers. Mitelman (1994)
reported 50 cases with clonal chromosome aberrations. More
recently, Bardi et al (1995), in a cytogenetic study of 13 endome-
trial carcinomas, showed that trisomy or tetrasomy 1, trisomy 2, 7,
10 and 12, and loss ofchromosome 22 were common alterations.
We have studied chromosome constitutions of 15 endometrial
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tumour) using cytogenetic analysis and fluorescence in situ
hybridization (FISH) in order to identify the various patterns of
chromosome abnormalities and their relationship with different
histological types.
MATERIALS AND METHODS
Fifteen endometrial carcinomas surgically resected at Ospedale di
Circolo in Varese between January 1994 and June 1995 were
investigated cytogenetically. Solid tumour samples were obtained
from the patients at the time oftheirinitial laparatomy. All patients
were newly diagnosed as having previously untreated epithelial
endometrial cancer.
The surgically removed specimens were sent under sterile condi-
tions for histological and cytogenetic investigations. Sampling for
histopathological and cytogenetic studies was performed in
contiguous areas and from a non-necrotic portion of the primary
endometrial carcinomas.
Theclinical andhistological characteristics ofthetumours studied,
of both type I and type II, are summarized in Table 1. Staging was
established according to the FIGO guidelines (Creasman, 1989).
Histological study
After formalin fixation and paraffin embedding, haematoxylin-
and eosin-stained tumours were classified according to the criteria
of the WHO (Scully et al, 1994). Malignant neoplasms were
subdivided into well (GI), moderately (G2) and poorly differenti-
ated (G3). The grade (G) was based on both nuclear and architec-
tural features as recommended by the FIGO Staging System
(Creasman, 1989) and WHO (Scully et al, 1994). The mitotic
index of each tumour was estimated on ten high-power fields
(HPF) at a magnification of400 x.
Cytogenetics study
Chromosome analysis was performed in each case on direct prepa-
rations using the method reported by Dalpra et al (1986), with some
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Table 1 Histopathological aspects of endometrial cancers
Case no. Age Clinical subtype Histotype G Mitotic index (10 x HPF) Stage
1 49 Endometrioid 2 NE IC
2 65 Endometrioid 1 1 IC
3 60 Endometrioid 1 Oa IB
4 62 Endometrioid 3 22 IB
5 56 Endometrioid 2 10 IC
6 57 Endometrioid 2 22 IC
7 71 Endometrioid with 2 3 3C
squamous
differentiation
8 67 Endometrioid with 3 6 IC
squamous
differentiation
9 84 Endometrioid 2 9 IC
10 62 Endometrioid 2 3 IB
11 84 Endometrioid 2 17 IB
12 87 - Mixed mullerian 3 80 IC
13 69 11 Serous papillary 2 0 IB
14 73 11 Serous papillary 3 11 IB
15 68 11 Undifferentiated 3 14 IB
aEvaluated on 2 x HPF only. NE, not evaluable.
Table 2 Cytogenetic and FISH results
Case no. Histotype G Karyotype FISH analysis
1 Endometrioid 2 46,XX[5] Not performed
2 Endometrioid 1 46,XX [8] Normal chromosome 6 confirmed
3 Endometrioid 1 45, XX, -18 [3]/46,XX [8] Normal chromosome 6 confirmed
4 Endometrioid 3 46,XX, del(6)(q24-qter) [3]/46,XX [3] 6q deletion confirmed
5 Endometrioid 2 46,XX,del(1 7)(pl2-pter) [3]/46,XX [3] Not performed
6 Endometrioid 2 46,XX, del(6)(q25-qter) [6]/46,XX [5] 6q deletion confirmed
7 Endometrioid with 2 40-45,XX, +1 [2], - 19 [4] [cp5] Gain of chromosome 1 confirmed
squamous differentiation
8 Endometrioid with 3 43-45,XX, del(6) (q25-qter)[4], t(9;11)[4][cp7]/46,XX[4] Not available
squamous differentiation
9 Endometrioid 2 34-44,XX,-X [3], -13 [3], -15 [5], - 20 [3], - 21 [5], - 22[3] [cp6] Normal chromosome 6 confirmed
10 Endometrioid 2 39-46,XX,-6 [3], del(6) (q21-qter) [5], -15 [3] [cp7] Not performed
11 Endometrioid 2 46-48,XX, + 1 [6], del(6) (q25-qter) [4], -8 [3], -9 [4], +11 [2], Gain of chromosome 1 confirmed
-12 [3] [cp6]
12 Mixed mullerian 3 46-56, XX, t(1 ;?) [8], + 2[4], + 3 [3], -6 [3], del (6)(q24-qter) [3], Translocation of chromosome 1 and 6q
- 12 [3], add(12)(p?) [3], - 16 [3], - 18 [71, - 19 [6], - 20 [5] [cp8] deletion confirmed
13 Serous papillary 2 38-46,XX, - 18 [3], del(6) (q25-qter) [7] [cp7]/17-32,X,+6 [3], 6q deletion confirmed
-7 [2], - 8 [4], - 10 [3], + 14 [3], - 15 [2], - 17 [3], +20 [3] [cp5]
14 Serous papillary 3 Not analysable Chromosome 6 fragmentation confirmed
15 Undifferentiated 3 Not analysable Chromosome 6 fragmentation confirmed
modifications. Suspensions of tumour cells were obtained by
mincing small pieces ofthe tumour in aPetri dish and incubated for
72 h at37°C with 5% carbon dioxide. The medium used was RPMI-
1640 supplemented with 15% fetal calf serum, 1% penicillin and
streptomycin, 1% L-glutamine, insulin (I gg ml-1), cholera toxin
(100 ng ml-') andepidermal growth factor(1 ng ml-') (Pejovic et al,
1989). The tumour cells were exposed overnight to colcemid
(0.02 gg ml-') and harvested by hypotonic treatment in 1% sodium
citrate andrepeated fixations in methanol-acetic acid (3:1). The cell
suspension was obtained using a solution of 70% acetic acid and
the metaphase spread was performed on a warm plate at 400C.
Karyotype analysis was performed using the QFQ banding tech-
nique (ISCN, 1975). A minimum offive metaphases (generally ten)
were analysed. Structural abnormalities were identified as clonal if
found in two or more cells. Numerical changes (two or more cells
for gain, three or more cells for loss) were described relative to the
ploidy ofthe abnormal modal population, as recommended (ISCN,
1995). When different tumour cell populations were identified the
modal chromosome number ofeach population was reported.
Probes
Four types of probes were used: a biotin-labelled whole chromo-
some painting (WCP) for chromosome 1, a digoxigenin-labelled
WCP for chromosome 6 (ONCOR) and two yeast artificial chro-
mosome (YAC) clones mapped in 6q26-27 (ICRF 17AI12 and
74E9; R Taramelli in preparation). These YAC clones are located
in a region approximately 2 cM between markers D6S149 and
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Figure 1 Endometrial adenocarcinoma (case 4). (A) Histological features,
complex proliferation of crowded neoplastic glands lined by tall columnar
epithelium (H-EX400). (B) QFQ-banded metaphase of case 4 showing 6q
deletion. (C) FISH with WCP for chromosome 6 showing different sizes of
two homologues
D6S193. YAC (DNA) probes were labelled with biotinylated
16-dUTP (Boehringer) using the random priming technique.
Fluorescence in situ hybridization (FISH)
FISH, using WCP ofchromosome 6 or WCP ofchromosome 1 and
YACs, was performed following the method of Pinkel et al (1986)
Figure 2 Serous papillary endometrial carcinoma (case 13). (A) Histological
aspect showing papillary pattern of growth and characteristic hobnail-shaped
cells (H-EX400). (B) OFO-banded metaphase of diploid cell line of case 13
showing 6q deletion and monosomy of chromosome 18. (C) Dual-colour
FISH showing loss of YACs mapped in the 6q27 region in the diploid cell line
with modifications. Slides were treatedwith RNAaseA(100 ggml-',
Sigma) for 1 h at 37°C, washed twice in 2 x SSC and dehydrated
through 70%, 95% and 100% ethanol. The chromosomal DNA was
denaturated in 70% formamide, 2 x SSC, pH 7.0, at 75°C for 5 min,
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dehydrated in an ice-cold ethanol series and airdried. Cot-I and YAC
DNA mixed with chromosome 6 paint were denaturated at 80°C for
10 min and preannealed for 2 h at 37°C. Hybridization was carried
out at 37'C ovemight in a humid chamber.
Slides were washed three times in 50% formamide at 42°C, 2 x
SSC, pH 7.0, and three times in 2 x SSC at 42°C. Hybridized
probes were detected by incubating slides at 37°C in a mixture of
rhodamine-antidigoxigenin (ONCOR) and fluorescein-avidin
DCS (Vector Laboratories). The amplification step was performed
with rabbit anti-sheep and anti-rabbit antibodies (ONCOR) for the
digoxigenin-labelled probes, and anti-avidin antibody (Vector) for
the biotin-labelled probes. After incubation, slides were washed
three times in 4 x SSC, 0.05% Tween 20, and then dehydrated
through an ethanol series. Finally, preparations were mounted in
an antifade solution containing DAPI or propidium iodide and
observed with a Leica DMR fluorescence microscope under a
triple-bandpass or FITC filter.
RESULTS
Conventional cytogenetic analysis
Conventional cytogenetic analyses oftumours from all patients are
summarized in Table 2. Clonal chromosome aberrations were
found in 11 endometrial cancers, whereas two cancers displayed
normal karyotypes. The modal chromosome number was in the
diploid range in all tumours with an abnormal karyotype. In four
cases normal clones were detected together with clones with a
single anomaly (cases 3, 4, 5 and 6). Two carcinornas (cases 14
and 15) shared chromosome instability and the karyotypes were
not analysable.
In seven cases (7, 8, 9, 10, 11, 12, 13) composite karyotypes
were observed and in two of these (cases 8 and 13) two different
clones were shown.
Chromosome 1 was involved as numeric and structural anom-
alies in three cases (7, 11, 12). Loss of the entire chromosome 18
was identified in three cases (3, 12 and 13), one of which (case 3)
showed a monosomy ofchromosome 18 as the sole anomaly.
The most frequent chromosome abnormality detected in our
series ofendometrial neoplasms was 6q deletion (7 cases out of 13).
This type of aberration was present as a sole anomaly in two cases
[cases 4 (Figure 1) and 6] or in association with other types of
abnormalities in the remaining five cases (cases 8, 10, 11, 12, 13).
The position ofthe proximal breakpoint varied between bands 6q21
and 6q25, breakpoints at 6q24 and 6q25 being most frequently
involved.
FISH analysis
FISH analysis using WCP for chromosome 1 confirmed the pres-
ence of a translocation in case 12 and gain of chromosome 1 in
cases 7 and 11.
FISH analysis using WCP for chromosome 6 as probe was
performed in eight cases (2, 4, 6, 9, 12, 13, 14, 15), in four ofthese
(cases 4, 6, 12, 13) the loss ofpart ofthe long arm ofchromosome
6 was confirmed by the presence of two FITC signals of different
sizes (Figure IC). In the remaining two cases (14 and 15) the FITC-
conjugated chromosome 6 probe painted different chromosome
regions (more than 3 and 4) of small size, suggesting a chromo-
some fragmentation.
We also performed a dual-colour FISH analysis using simulta-
neously WCP for chromosome 6 and YACs from the 6q27 region
as probes. It was possible to apply this combined analysis to five
cases [3, 4, 8, 12, 13 (Figure 2)] and molecular loss of the 6q27
region was detected in three ofthem (cases 4, 12 and 13). In case 3
normal chromosome 6 was observed and unfortunately we could
not evaluate 6q27 molecular loss in case 8 because insufficient
metaphases were available.
DISCUSSION
Our data demonstrate that cytogenetic anomalies are frequently
detected in endometrial neoplasms belonging to both type I and
type H according to Kurman et al (1994). Eleven of 13 endometrial
analysable cancers studied were cytogenetically abnormal. In
six cases a mosaic constitution showing clones with normal-
aneuploid chromosome constitution (cases 3, 4, 5, 6 and 8) and
haploid- near- diploid complement (case 13) were identified.
Two endometrial neoplasms had chromosome instability. Cells of
these tumours typically contained fragmented chromosomes,
quadriradial and/or triradial, and varying complex structural
rearrangements preventing complete karyotype descriptions. This
chromosomal pattem is typical of ovarian carcinomas (Trent et al,
1985; Thompson et al, 1994), but it has not been described in
endometrial cancer.
The catalogue of Mitelman (1994) reported 50 uterine carci-
nomas, the majority of which showed simple karyotypes.
Abnormalities of chromosome 1 and particularly trisomy or tetra-
somy of lq have been described. In addition, abnormalities such as
trisomies 2, 7, 10 and 12 have also been found. Although abnor-
malities of chromosome 1 are reported as recurrent aberrations in
endometrial cancers (Couturier et al, 1986; Yoshida et al, 1986;
Shah et al, 1994; Bardi et al, 1995), in our study chromosome 1
anomalies were identified in only three cases showing endo-
metrioid and mixed mullerian histotypes. These different results
may be partly explained by the different technical approach in the
study ofchromosomal anomalies. We studied chromosome consti-
tutions of endometrial cancers using direct preparations and it is
well known that this technique identifies cells in active prolifera-
tion (Dalpra et al, 1986; D'Alessandro et al, 1994; Westphal et al,
1994; Bardi et al, 1995; Rosenberg et al, 1995). We found this
technique to be more efficient than short-term cultures in identi-
fying the chromosome abnormalities in cancer cells avoiding those
of contaminating tissues.
6q deletion is the cytogenetic abnormality most frequently
involved in our cases (7 out of 13 cases), and this anomaly was
identified in neoplasms showing endometrioid, mixed mullerian
and serous papillary morphological features. It is well known that
anomalies of 6q are involved in several human malignancies, and
occur at high frequency in serous papillary ovarian carcinomas
(Sato et al, 1991; Saito et al, 1992; Foulkes et al, 1993; Mitelman,
1994; Orphanos et al, 1995; Tibiletti et al, 1997). Molecular
studies employing loss of heterozygosity (LOH) analysis allowed
a region of common deletion to be defined that spans markers
D6S149 and D6S193 located in 6q27 (Saito et al, 1992). So far,
this chromosome abnormality has not been strictly related to the
endometrial carcinomas, although different authors have reported,
separately, chromosome 6 deletion in serous papillary, endo-
metrioid and mixed mullerian endometrial cancers (Musilova and
Michalova, 1986; Milatovich et al, 1990; Shah et al, 1994; Bardi et
al, 1995). We identified a high proportion of endometrial carci-
nomas showing cytogenetic 6q deletion, and this was confirmed
by FISH analysis using YACs from 6q27 as probes. This technique
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demonstrated the same allelic loss of a chromosomal region
frequently found in ovarian carcinomas.
The finding ofcytogenetically normal clones (cases 1, 2, 3, 4, 5,
6 and 8) suggests that more subtle mutations, precluding their
assessment by our approach, may be involved in endometrial
cancers. The possibility that we analysed the karyotype of non-
tumoral cells can be excluded because, on direct preparations of
non-tumoral tissues, mitoses were never observed precluding their
cytogenetic analysis.
Our findings demonstrate a large heterogeneity in chromosome
constitution of endometrial cancer, which may be related to
different histological subtypes. The tumour karyotypes of serous
papillary (type II cancer) and mixed muillerian were more complex
than those of endometrial carcinomas (type I cancer), and this
finding may be associated with a less favourable prognosis of the
former neoplasm.
On the contrary, no relationships between chromosome consti-
tution and grade, proliferative status and clinicopathological stage
were observed, but clearly more cases need to be analysed in order
to achieve statistical significance.
The 6q deletion was detected in serous papillary and
endometrioid carcinomas of the endometrium that show morpho-
logical similarities with the ovarian counterparts. Interestingly, the
tumour-suppressor gene(s) mapped to 6q27 by allelotype studies
(Sato et al, 1991; Saito et al, 1992; Foulkes et al, 1993), and
involved in the pathogenesis ofovarian tumours, might also play a
role in endometrial tumours. This is not unexpected given the
common histogenesis ofmuillerian structures.
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